Clinical TrialMay 26, 2026, 08:47 AM
PRF Technologies PRF-110 Shows Sustained 72-Hour Analgesia in Preclinical Study
AI Summary
PRF Technologies announced positive results from a preclinical study for its lead product candidate, PRF-110, an extended-release ropivacaine formulation for post-operative pain. In a head-to-head comparison in domestic pigs, PRF-110 demonstrated sustained 72-hour analgesic activity comparable to ZYNRELEF, an approved benchmark. The company highlighted PRF-110's ropivacaine-only, NSAID-free formulation as a potential advantage due to ropivacaine's lower cardiac toxicity compared to bupivacaine.
Key Highlights
- PRF-110 demonstrated sustained 72-hour analgesic activity comparable to ZYNRELEF in a head-to-head preclinical study.
- The study was conducted in a validated pig incisional pain model, comparing PRF-110 to an approved benchmark.
- PRF-110 is a proprietary, ropivacaine-only, NSAID-free extended-release formulation.
- Ropivacaine has demonstrated lower cardiac toxicity than bupivacaine in non-clinical pharmacology studies.
- Both PRF-110 and ZYNRELEF produced clear reductions in pain-related measures over 72 hours.
- PRF-110's safety and local tolerability profile in pigs was consistent with prior preclinical experience.
- The company will use these findings to inform PRF-110's future development and regulatory strategy.
Price Impact
More from PRFX